Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1014 participants.
Also called NCT02320721
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,014 participants
- Sponsor
- Registry
-
NCT02320721
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Canada, Colombia, France, Germany, Hungary, Italy, Japan, Mexico, Peru, Poland, Romania, South Korea, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02320721. Randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2017-07-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
- Acronym
- SENIOR
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin Glargine (HOE901 - U300)
- Intervention (Drug)
- Insulin Glargine (HOE901 - U100)
- Intervention (Drug)
- Background therapy
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02320721- Content hash
87539cd63bd872c9c199d1d5c3dd8ab6724f79ba30e6139ddce67ceb703cacbe